2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2814-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JINWOO LEE und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Cagrilintide is a long-acting amylin analog developed for obesity and metabolic diseases. Combination therapy with GLP-1 receptor agonists, including semaglutide, has demonstrated enhanced weight reduction through complementary mechanisms compared with GLP-1 monotherapy. Current development strategies rely on weekly administration of each component, typically requiring separate storage and injection. While a once-monthly, long-acting co-formulation could reduce injection burden, improve adherence, and enhance treatment convenience, co-formulation presents physicochemical instability risks including aggregation or precipitation.
Methods
Long-acting Cagri-Sema Injectables were prepared using biodegradable polymers via an emulsion-based microsphere fabrication process. A single-process manufacturing approach was applied to enable simultaneous incorporation of both Cagri-Sema within one production workflow. The pharmacokinetics of Cagri-Sema were evaluated in rats, and plasma concentrations of cagrilintide and semaglutide were maintained for more than 28 days.
Results
Both cagrilintide and semaglutide remained stable when incorporated through the single-process manufacturing approach, with no excessive initial burst release. Stability was also maintained in both co-encapsulated and individually encapsulated microspheres supporting feasibility of combination monthly administration. In rat PK studies of Cagri-Sema microspheres after a single injection, plasma cagrilintide and semaglutide concentration was kept more than 28 days.
Conclusion
The biodegradable microsphere platform enables once-monthly, combination of Cagri-Sema through a single-process manufacturing approach. By reducing injection frequency from weekly dual administration to monthly injection, this strategy may improve treatment convenience and adherence in long-acting combination therapy development for obesity and metabolic disease. Disclosure J. Lee: None. B. Kim: None. E. Seol: None. H. Lee: None.
Zitieren
APA
LEE, J., KIM, B., SEOL, E., & LEE, H. (2026). 2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2814-lb
Vancouver
LEE J, KIM B, SEOL E, LEE H. 2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2814-lb
BibTeX
@article{LEE2026,
author = {LEE, JINWOO and KIM, BOYEON and SEOL, EUNYOUNG and LEE, HEEYONG},
title = {2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2814-lb}
}
EUVIMED